Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Induction of mucosal immunity via intranasal administration is a vaccination strategy that delivers antigens through the nasal route to stimulate immune responses at mucosal surfaces, particularly in the respiratory tract. This approach aims to generate both local (mucosal) and systemic immunity, providing protection at the primary entry point for many pathogens. It relies on the activation of NALT, production of secretory IgA, and induction of tissue-resident memory cells.
Antigen presentation in NALT, activation of B and T cells, production of secretory IgA, induction of tissue-resident memory cells.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mucosal Immunity Induction via Intranasal Administration (Intranasal Mucosal Immunity).